Focus:
News
-
25 June 2019
C4XD collaborates with PhoreMost on Parkinson’s Disease drugs
C4X Discovery (C4XD) has partnered with UK-based biopharmaceutical company PhoreMost to accelerate the Parkinson’s Disease drug discovery pipeline.
-
25 June 2019
Transplant reports positive results in kidney device trial
Transplant Biomedicals has reported positive interim results of the first-in-human clinical trial of the Vivian device in kidney transplantation.
-
25 June 2019
Creo Medical receives orders for Speedboat device
Creo Medical Group has received its first commercial orders for its Speedboat device from two hospitals in the US.
-
24 June 2019
CMR Surgical and LifeHealthcare bring Versius robotic surgery to Australia
CMR Surgical and LifeHealthcare are teaming up to bring the Versius robotic keyhole surgery system to Australia and New Zealand.
-
24 June 2019
Immugenyx develops new type of humanised mouse ApbHC
Immugenyx, a wholly-owned subsidiary of Hemogenyx Pharmaceuticals, has developed a new type of humanised mouse called Advanced peripheral blood Hematopoietic Chimera (ApbHC) to help develop treatments against unknown human-specific pathogens.
-
24 June 2019
RTR Urology offers innovative new therapy for bladder cancer
21st Century Oncology unit RTR Urology is offering a new treatment using ‘blue light cystoscopy’ technology for its patients.
-
24 June 2019
SCIEX, EluciData agree to address metabolomics research challenges
Life science analytical technologies company SCIEX has announced a co-marketing agreement with disruptive integrated Omics platform company EluciData to address the challenges faced by metabolomics researchers.
-
21 June 2019
Breakthrough biomarker blood test for ovarian cancer on the horizon
The majority of women who undergo surgery for suspected ovarian cancer do not actually have the disease, but these unnecessary surgeries could soon be reduced thanks to a novel blood...
-
21 June 2019
CDT licenses Klue’s behavioural software for diabetes treatment
University of Virginia’s (UVA) Center for Diabetes Technology (CDT) has licensed Klue's gesture sensing and behavioural analytics software for a proposed clinical trial to further diabetes treatment.
-
21 June 2019
Resolution to create biopsy test as companion diagnostic for niraparib
Resolution Bioscience has collaborated with Janssen Research & Development to develop the Resolution HRD liquid biopsy assay as a companion diagnostic for PARP inhibitor, niraparib.